SCHEMBL868239

SCHEMBL868239

F[C]1CCC1(F)F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL575166 0.76
SCHEMBL575066 0.74
SCHEMBL16792400 0.72
SCHEMBL60584 0.70
SCHEMBL252712 0.69
SCHEMBL7095754 0.69
SCHEMBL15272097 0.67
SCHEMBL1578894 0.67
SCHEMBL7094128 0.65
SCHEMBL17474482 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116514835-A Organic photoelectric compound, preparation method and application thereof 南开大学 2023-08-01 CN disclosed
US-20200283439-A1 TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES AbbVie Deutschland GmbH & Co. KG (DE) 2020-09-10 US disclosed
EP-3636651-A1 HEXAHYDROPYRAZINOBENZ- OR -PYRIDO-OXAZEPINES CARRYING AN OXYGEN-CONTAINING SUBSTITUENT AND USE THEREOF IN THE TREATMENT OF 5-HT2C-DEPENDENT DISORDERS AbbVie Deutschland GmbH & Co. KG (DE) 2020-04-15 EP disclosed
US-20190135777-A1 QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR AbbVie Deutschland GmbH & Co. KG (DE) 2019-05-09 US disclosed
US-20190071443-A1 TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES AbbVie Deutschland GmbH & Co. KG (DE) 2019-03-07 US disclosed
US-20190048007-A1 TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES AbbVie Deutschland GmbH & Co. KG (DE) 2019-02-14 US disclosed
US-10160744-B2 Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-HT6 receptor AbbVie Deutschland GmbH & Co. KG (DE) 2018-12-25 US disclosed
US-20180339996-A1 HEXAHYDROPYRAZINOBENZ- OR -PYRIDO-OXAZEPINES CARRYING AN OXYGEN-CONTAINING SUBSTITUENT AND USE THEREOF IN THE TREATMENT OF 5-HT2C-DEPENDENT DISORDERS AbbVie Deutschland GmbH & Co. KG (DE) 2018-11-29 US disclosed
US-10118926-B2 Tricyclic quinoline and quinoxaline derivatives AbbVie Deutschland GmbH & Co. KG (DE) 2018-11-06 US disclosed
US-10100048-B2 Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors AbbVie Deutschland GmbH & Co. KG (DE) 2018-10-16 US disclosed
EP-0851861-A1 SUBSTITUTED 1-AMINO-3-PHENYLURACIL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS HERBICIDES BAYER AG (DE) 1998-07-08 EP disclosed
WO-1998025909-A1 3-AMINO-1-CYANOPHENYL-URACILS BAYER AKTIENGESELLSCHAFT (DE) 1998-06-18 WO disclosed
EP-0842155-A1 SUBSTITUTED AMINOURACILS BAYER AG (DE) 1998-05-20 EP disclosed
WO-1998006706-A1 SUBSTITUTED P-TRIFLUOROMETHYLPHENYLURACILS BAYER AKTIENGESELLSCHAFT (DE) 1998-02-19 WO disclosed
WO-1997009319-A1 SUBSTITUTED 1-AMINO-3-PHENYLURACIL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS HERBICIDES BAYER AKTIENGESELLSCHAFT (DE) 1997-03-13 WO disclosed
WO-1997005116-A1 SUBSTITUTED AMINOURACILS BAYER AKTIENGESELLSCHAFT (DE) 1997-02-13 WO disclosed
WO-1997001541-A1 SUBSTITUTED CYANOPHENYL URACILS BAYER AKTIENGESELLSCHAFT (DE) 1997-01-16 WO disclosed
EP-0409638-B1 Anthraquinone dyes having alkylsulfonylamino substituents MINNESOTA MINING & MFG (US) 1994-08-31 EP disclosed
US-5034547-A Colorfastness MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1991-07-23 US disclosed
EP-0409638-A1 Anthraquinone dyes having alkylsulfonylamino substituents MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1991-01-23 EP disclosed